Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The company is headquartered in Fremont, California and currently employs 40 full-time employees. The company went IPO on 2015-01-27. The firm is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. The company is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.

Industry: Pharmaceutical Preparations Peers: Abbott Laboratories QUANTRX BIOMEDICAL CORP AMERICAN BIO MEDICA CORP THC Therapeutics, Inc. Escalon Medical Corp